Latest Pharma Insights
Abivax Targets FDA Filing After Positive Phase III UC Data But Malignancy Questions Hit Shares
Attention is now shifting to how regulators, physicians and investors interpret malignancy findings that overshadowed an otherwise successful readout.
Scrip - June 2, 2026
Attention is now shifting to how regulators, physicians and investors interpret malignancy findings that overshadowed an otherwise successful readout.
Scrip - June 2, 2026
ASCO: Data Presentations (And An Approval) Illustrate Competitive TROP2 Race
Gilead Sciences, Daiichi Sankyo/AstraZeneca and Merck/Kelun all showcased their TROP2-directed antibody-drug conjugates at the ASCO meeting.
Scrip - June 2, 2026
Gilead Sciences, Daiichi Sankyo/AstraZeneca and Merck/Kelun all showcased their TROP2-directed antibody-drug conjugates at the ASCO meeting.
Scrip - June 2, 2026
Outlook Eyes Rapid FDA Approval For Ophthalmic Bevacizumab With Refiled BLA
Outlook Therapeutics has once again resubmitted its filing for its bevacizumab-based Lytenava ophthalmology treatment to the FDA, following the favorable outcome of a recent dispute resolution process. A PDUFA date and decision are expected within 60 days.
Generics Bulletin - June 2, 2026
Outlook Therapeutics has once again resubmitted its filing for its bevacizumab-based Lytenava ophthalmology treatment to the FDA, following the favorable outcome of a recent dispute resolution process. A PDUFA date and decision are expected within 60 days.
Generics Bulletin - June 2, 2026
Apotex Aims For Over C$1bn As It Launches IPO
Apotex has revealed financial details of its recently-announced IPO, with the Canadian generics and biosimilars giant seeking proceeds of more than C$1bn in a move that would value the firm at more than C$5bn.
Generics Bulletin - June 2, 2026
Apotex has revealed financial details of its recently-announced IPO, with the Canadian generics and biosimilars giant seeking proceeds of more than C$1bn in a move that would value the firm at more than C$5bn.
Generics Bulletin - June 2, 2026
Celltrion Uses Canada To Crack Open Cosentyx Market
Celltrion’s Canadian filing for CT-P55 looks to give it an early route into North America’s major Cosentyx biosimilar opportunity, as Western rivals remain absent and Asian developers define the field.
Generics Bulletin - June 2, 2026
Celltrion’s Canadian filing for CT-P55 looks to give it an early route into North America’s major Cosentyx biosimilar opportunity, as Western rivals remain absent and Asian developers define the field.
Generics Bulletin - June 2, 2026
PCOS Renamed PMOS: What The Reclassification Means For Drug Development And Market Access
The global consensus reclassifying polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome (PMOS) is opening new fronts in drug development, at-home diagnostics, and chronic disease management.
In Vivo - June 2, 2026
The global consensus reclassifying polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome (PMOS) is opening new fronts in drug development, at-home diagnostics, and chronic disease management.
In Vivo - June 2, 2026
GRAIL’s Galleri Cleared Secondary Bars At ASCO, But Primary Endpoint Miss Remains
Galleri met multiple secondary endpoints at ASCO 2026. Still, the NHS-Galleri trial's failure to hit its primary combined Stage III/IV endpoint leaves FDA reviewers and payers weighing compelling secondary data against a key statistical shortfall.
Medtech Insight - June 2, 2026
Galleri met multiple secondary endpoints at ASCO 2026. Still, the NHS-Galleri trial's failure to hit its primary combined Stage III/IV endpoint leaves FDA reviewers and payers weighing compelling secondary data against a key statistical shortfall.
Medtech Insight - June 2, 2026
Agios Secures Oscotec’s Next Generation SYK Inhibitor In $665m Deal
Agreement expands Agios's rare hematology portfolio in high-need area and marks another major global alliance involving Oscotec, validating the Korean industry's rising competitiveness in innovative drug development.
Scrip - June 2, 2026
Agreement expands Agios's rare hematology portfolio in high-need area and marks another major global alliance involving Oscotec, validating the Korean industry's rising competitiveness in innovative drug development.
Scrip - June 2, 2026
ASCO: CStone’s First-In-Class Trispecific Shows Strong Activity In 1L NSCLC
Strong efficacy signs for Alphamab’s anti-HER2 bispecific in the neoadjuvant setting lay a firm foundation for its use in early breast cancer, while early data for CStone’s first-in-class trispecific offer a strong basis for a planned global Phase III trial in lung cancer.
Scrip - June 2, 2026
Strong efficacy signs for Alphamab’s anti-HER2 bispecific in the neoadjuvant setting lay a firm foundation for its use in early breast cancer, while early data for CStone’s first-in-class trispecific offer a strong basis for a planned global Phase III trial in lung cancer.
Scrip - June 2, 2026
Abivax Targets FDA Filing After Positive Phase III UC Data But Malignancy Questions Hit Shares
Attention is now shifting to how regulators, physicians and investors interpret malignancy findings that overshadowed an otherwise successful readout.
Scrip - June 2, 2026
Attention is now shifting to how regulators, physicians and investors interpret malignancy findings that overshadowed an otherwise successful readout.
Scrip - June 2, 2026
ASCO: Data Presentations (And An Approval) Illustrate Competitive TROP2 Race
Gilead Sciences, Daiichi Sankyo/AstraZeneca and Merck/Kelun all showcased their TROP2-directed antibody-drug conjugates at the ASCO meeting.
Scrip - June 2, 2026
Gilead Sciences, Daiichi Sankyo/AstraZeneca and Merck/Kelun all showcased their TROP2-directed antibody-drug conjugates at the ASCO meeting.
Scrip - June 2, 2026
Agios Secures Oscotec’s Next Generation SYK Inhibitor In $665m Deal
Agreement expands Agios's rare hematology portfolio in high-need area and marks another major global alliance involving Oscotec, validating the Korean industry's rising competitiveness in innovative drug development.
Scrip - June 2, 2026
Agreement expands Agios's rare hematology portfolio in high-need area and marks another major global alliance involving Oscotec, validating the Korean industry's rising competitiveness in innovative drug development.
Scrip - June 2, 2026
ASCO: CStone’s First-In-Class Trispecific Shows Strong Activity In 1L NSCLC
Strong efficacy signs for Alphamab’s anti-HER2 bispecific in the neoadjuvant setting lay a firm foundation for its use in early breast cancer, while early data for CStone’s first-in-class trispecific offer a strong basis for a planned global Phase III trial in lung cancer.
Scrip - June 2, 2026
Strong efficacy signs for Alphamab’s anti-HER2 bispecific in the neoadjuvant setting lay a firm foundation for its use in early breast cancer, while early data for CStone’s first-in-class trispecific offer a strong basis for a planned global Phase III trial in lung cancer.
Scrip - June 2, 2026
GRAIL’s Galleri Cleared Secondary Bars At ASCO, But Primary Endpoint Miss Remains
Galleri met multiple secondary endpoints at ASCO 2026. Still, the NHS-Galleri trial's failure to hit its primary combined Stage III/IV endpoint leaves FDA reviewers and payers weighing compelling secondary data against a key statistical shortfall.
Medtech Insight - June 2, 2026
Galleri met multiple secondary endpoints at ASCO 2026. Still, the NHS-Galleri trial's failure to hit its primary combined Stage III/IV endpoint leaves FDA reviewers and payers weighing compelling secondary data against a key statistical shortfall.
Medtech Insight - June 2, 2026
DSM-Firmenich Helps Prep Brands for BEMT US Launch – Senior Manager
Dutch company DSM-Firmenich is helping its brand partners with ‘launch readiness’ for their skin care containing BEMT, also known as PARSOL Shield.
HBW Insight - June 1, 2026
Dutch company DSM-Firmenich is helping its brand partners with ‘launch readiness’ for their skin care containing BEMT, also known as PARSOL Shield.
HBW Insight - June 1, 2026
Galderma’s Launch Of Differin Epiduo OTC Switch, Unlike Differin, Won’t Have Exclusivity
Adapalene/benzoyl peroxide acne gel isn’t receiving three-year market exclusivity as part of FDA’s recent approval of Galderma Labs’ NDA. Galderma expects to launch Differin Epiduo during summer this year “with broad availability across both in-store and online channels.”
HBW Insight - June 1, 2026
Adapalene/benzoyl peroxide acne gel isn’t receiving three-year market exclusivity as part of FDA’s recent approval of Galderma Labs’ NDA. Galderma expects to launch Differin Epiduo during summer this year “with broad availability across both in-store and online channels.”
HBW Insight - June 1, 2026
Cooper Acquires Spain’s ‘Number-One Analgesic’ As Ferrer Exits OTC
As Ferrer quits OTC to focus on pharma, Cooper Consumer Health gains leading Spanish analgesic brand Gelocatil to further enhance its own growing portfolio in the country.
HBW Insight - June 1, 2026
As Ferrer quits OTC to focus on pharma, Cooper Consumer Health gains leading Spanish analgesic brand Gelocatil to further enhance its own growing portfolio in the country.
HBW Insight - June 1, 2026
Outlook Eyes Rapid FDA Approval For Ophthalmic Bevacizumab With Refiled BLA
Outlook Therapeutics has once again resubmitted its filing for its bevacizumab-based Lytenava ophthalmology treatment to the FDA, following the favorable outcome of a recent dispute resolution process. A PDUFA date and decision are expected within 60 days.
Generics Bulletin - June 2, 2026
Outlook Therapeutics has once again resubmitted its filing for its bevacizumab-based Lytenava ophthalmology treatment to the FDA, following the favorable outcome of a recent dispute resolution process. A PDUFA date and decision are expected within 60 days.
Generics Bulletin - June 2, 2026
Apotex Aims For Over C$1bn As It Launches IPO
Apotex has revealed financial details of its recently-announced IPO, with the Canadian generics and biosimilars giant seeking proceeds of more than C$1bn in a move that would value the firm at more than C$5bn.
Generics Bulletin - June 2, 2026
Apotex has revealed financial details of its recently-announced IPO, with the Canadian generics and biosimilars giant seeking proceeds of more than C$1bn in a move that would value the firm at more than C$5bn.
Generics Bulletin - June 2, 2026
Celltrion Uses Canada To Crack Open Cosentyx Market
Celltrion’s Canadian filing for CT-P55 looks to give it an early route into North America’s major Cosentyx biosimilar opportunity, as Western rivals remain absent and Asian developers define the field.
Generics Bulletin - June 2, 2026
Celltrion’s Canadian filing for CT-P55 looks to give it an early route into North America’s major Cosentyx biosimilar opportunity, as Western rivals remain absent and Asian developers define the field.
Generics Bulletin - June 2, 2026
PCOS Renamed PMOS: What The Reclassification Means For Drug Development And Market Access
The global consensus reclassifying polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome (PMOS) is opening new fronts in drug development, at-home diagnostics, and chronic disease management.
In Vivo - June 2, 2026
The global consensus reclassifying polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome (PMOS) is opening new fronts in drug development, at-home diagnostics, and chronic disease management.
In Vivo - June 2, 2026